This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

HIV disease resulting in Kaposi's sarcoma카포시육종을 유발한 인체면역결핍바이러스병

Contents and key points
ItemDetails
A. Classification codesICD-10: B21.0 (HIV disease resulting in Kaposi's sarcoma) | Special Copayment Reduction: V103 (severe intractable disease, 5 years)
B. SynonymsHIV-associated Kaposi's sarcoma; AIDS-related Kaposi sarcoma; Epidemic Kaposi sarcoma; KS in HIV; HHV-8 associated vascular tumor in AIDS
C. Adult onsetLikelihood of adult onset: very high — AIDS-related Kaposi's sarcoma occurs mainly in HIV-infected adults and is most commonly diagnosed in MSM (men who have sex with men; gay and bisexual men) in the sexually active age range (20s–50s). It also occurs in HIV-infected children but is far more common in adults.
1. HistoryFirst described by Moricz Kaposi in 1872. Included in the first reported cases of AIDS in 1981. HHV-8 (KSHV) discovered in 1994. Incidence fell sharply after ART. Still a common AIDS-related cancer in Africa.
2. CausesCombined effect of HHV-8 (KSHV) infection and HIV-induced immunosuppression. HHV-8 is transmitted through sexual contact, saliva, and blood. HIV-induced collapse of Th1 immunity underlies HHV-8 reactivation and the development of KS.
3. GeneticsLatency genes of HHV-8 such as LANA, vFLIP, and vCyclin induce cell proliferation and inhibit apoptosis. NF-κB and MAPK pathways are activated. Host HLA polymorphisms and IL-6 and VEGF pathway genes influence susceptibility to KS.
4. General epidemiologyAIDS-related KS occurred in about 20–30% of HIV patients before ART. It decreased by more than 85% after ART. In some parts of Africa, KS is the most common cancer. Prevalence is high in MSM.
5. PathophysiologyHHV-8 infection of vascular endothelial cells (especially lymphatic endothelial cells) → tumorigenesis driven by latency proteins (LANA, vFLIP, vCyclin) → HIV-induced CD4 depletion impairs HHV-8 immune surveillance → Tat protein promotes proliferation of KS cells.
6. SymptomsPurple/brown papules, patches, and nodules of the skin; oral mucosal lesions; limb lymphedema (when the lymphatic system is involved); cough and dyspnea in pulmonary KS; abdominal pain and bloody stool in gastrointestinal KS; systemic wasting symptoms.
7. SignsCutaneous KS lesions (purple to reddish-brown, nodular, patch-like), oral KS, lymph node enlargement, lower limb lymphedema, nodules and pleural effusion on chest CT (pulmonary KS), gastrointestinal KS lesions on endoscopy. Decreased CD4, positive HHV-8 DNA.
8. ScreeningRegular inspection of skin lesions in HIV patients. HHV-8 serologic screening in patients with decreased CD4 (especially MSM). Active screening in regions at high risk for KS (sub-Saharan Africa).
9. DiagnosisSkin biopsy (spindle cell tumor; positive HHV-8 LANA-1 immunostaining is the standard). Staging evaluation with endoscopy, bronchoscopy, CT, etc. AIDS Clinical Trials Group (ACTG) staging system applied.
10. TreatmentEarly initiation of ART is first-line treatment. Limited cutaneous KS: local therapy (radiation, cryotherapy, intralesional vinblastine injection). Extensive/visceral KS: pegylated liposomal doxorubicin (first line), paclitaxel (second line).
11. PrognosisComplete remission of KS is possible with ART alone (especially skin-limited KS). Poor prognosis with visceral involvement. ACTG stage determines prognosis. Five-year survival has improved greatly in the ART era.
12. PreventionMaintaining CD4 with ART is most effective. Block HHV-8 transmission (condom use). Prevent immunosuppression in HHV-8 seropositive HIV patients. There is still no approved HHV-8 vaccine.
13. ReferencesBower M et al. Lancet Oncol 2014 and 9 others

1. History

Kaposi's sarcoma (KS) was first described in 1872 by the Hungarian-born Austrian dermatologist Moricz Kaposi (1837–1902) under the name "pigmented sarcoma." Kaposi reported five cases presenting clinically with multiple bluish-purple nodular and patch-like lesions of the lower limbs in elderly Jewish men and Mediterranean men. This form was later classified as "classic Kaposi's sarcoma" and is characterized by slow progression and a relatively favorable prognosis.

In the mid-20th century, it became known that KS occurs commonly in relatively young men in sub-Saharan Africa, especially the Congo (now the Democratic Republic of the Congo) and Uganda. This "endemic African type" showed a broad spectrum ranging from lower-limb-limited disease to generalized lymph node involvement. During the same period, "iatrogenic KS (transplant-associated KS)" was reported, occurring frequently in kidney transplant recipients taking immunosuppressants (especially calcineurin inhibitors), suggesting an association between immunosuppression and the development of KS.

The CDC record of the first official report of AIDS in 1981 (MMWR, June 1981) included cases of unusual Kaposi's sarcoma in young gay men in California. This "AIDS-related (epidemic) KS" was very aggressive, unlike the earlier classic and African types, with a rapid course, extensive skin and visceral involvement, and a background of extreme immunosuppression. During the early AIDS epidemic, KS developed in about 20–40% of MSM with HIV.

The most important discovery in the pathogenesis of KS was the 1994 discovery by Yuan Chang and Patrick Moore of a new herpesvirus in KS lesions—HHV-8 (Human herpesvirus 8), or Kaposi's sarcoma-associated herpesvirus (KSHV). This discovery transformed the understanding of the etiology of KS and established that KS arises from the combined effect of HHV-8 infection and immunosuppression. After the introduction of ART in 1996, the incidence of AIDS-related KS fell sharply in developed countries, by more than 85% compared with the early 1990s. However, in sub-Saharan Africa, in regions with inadequate access to ART, KS remains the most common AIDS-related malignancy and one of the most frequent adult cancers.


2. Causes

AIDS-related Kaposi's sarcoma arises from the combined effect of two essential factors: HHV-8 (KSHV) infection and HIV-induced immunosuppression.

HHV-8 (KSHV) infection

HHV-8 belongs to the genus Rhadinovirus of the subfamily Gammaherpesvirinae and was discovered in 1994 by Chang and Moore. Humans are the only natural host, and it is transmitted mainly through sexual contact (especially anal and oral sex) and saliva. Blood exposure (transfusion, needle sharing), vertical transmission (mother-to-child), and transmission through saliva between infants (endemic areas of Africa) are also possible. HHV-8 seroprevalence is <5% in the general Western population, 30–70% in sub-Saharan Africa, and 30–60% in HIV-infected MSM. HHV-8 infection is identified in all types of KS (classic, African, transplant-associated, AIDS-related), and KS does not occur without HHV-8.

Role of HIV and immunosuppression

HIV-induced immunosuppression is the key background to HHV-8 reactivation and the development of KS. When HHV-8-specific cytotoxic T-cell responses are lost owing to the decline in CD4+ T cells, HHV-8 switches from latency to lytic replication and KS lesions form. The HIV Tat protein is also known to directly promote the proliferation of KS cells. The chronic inflammation and cytokine environment caused by HIV (elevated IL-6, IL-10, and IFN-γ; increased VEGF) also contribute to the development and progression of KS. AIDS-related KS carries the highest risk when CD4 is <200/μL, especially <100/μL.


3. Genetics

AIDS-related Kaposi's sarcoma is not a hereditary disease. However, the molecular biology of HHV-8 and host genetic factors are importantly involved in susceptibility to KS.

Oncogenic mechanisms of HHV-8 latency genes

Latency proteins expressed in HHV-8-infected cells are critically involved in cellular transformation. LANA (Latency-Associated Nuclear Antigen) maintains the HHV-8 episome on host chromosomes and induces cell proliferation by inhibiting p53 and Rb. vFLIP (viral FLICE-inhibitory protein) persistently activates the NF-κB pathway, inducing anti-apoptotic effects and immune evasion. vCyclin binds CDK6 to promote the G1/S transition of the cell cycle and accelerate cell proliferation. LANA-2 (vIRF-3) inhibits interferon regulatory factor, blocking the antiviral immune response. Among lytic proteins, vIL-6 promotes cell proliferation and angiogenesis (VEGF induction) through the human IL-6 receptor.

Host genetic factors

HLA class I genotype influences susceptibility to KS. In particular, an association between HLA-B*18 and increased KS risk has been reported in some studies. VEGF (vascular endothelial growth factor) gene polymorphisms and IL-6 promoter polymorphisms are associated with the development and progression of KS. VEGF and IL-6 are key mediators of KS cell proliferation and angiogenesis. Polymorphisms of chemokine receptors such as CCR5 and CXCR4 may indirectly affect HHV-8 cell entry and KS risk.


4. General epidemiology

In the pre-ART era, AIDS-related Kaposi's sarcoma was the most common AIDS-defining malignancy in HIV-infected individuals. The incidence was especially high in HIV-infected MSM; before ART in the United States, KS developed in about 20–30% of HIV-infected MSM.

Epidemiologic changes after ART

After the introduction of ART in 1996, the incidence of AIDS-related KS fell sharply in developed countries, by about 85–90% compared with the early 1990s. In the United States, the annual incidence of AIDS-related KS decreased from about 15–20 per 100,000 MSM before ART to about 2–3 per 100,000 MSM after ART. A similar downward trend has been observed in Europe. However, in sub-Saharan Africa, where ART is not sufficiently available, KS remains the most common AIDS-related malignancy and a major cause of adult cancer. It has been reported that KS accounts for 30–50% of all cancer registrations in Uganda, Zambia, Zimbabwe, and elsewhere.

Epidemiology in Korea

AIDS-related KS is rare in Korea. HHV-8 seroprevalence in Korea is very low (<1% in the general population) and is also known to be lower in HIV patients than in the West. Although the proportion of MSM among HIV-infected individuals in Korea is high, the prevalence of HHV-8 is low, so AIDS-related KS is relatively rare. Most reported domestic cases were foreigners or people with a history of staying abroad.


5. Pathophysiology

The pathogenesis of AIDS-related Kaposi's sarcoma is the combined effect of HHV-8-induced transformation of vascular endothelial cells and HIV-induced impairment of immune surveillance.

Cellular infection and latency of HHV-8

HHV-8 infects mainly lymphatic endothelial cells and transforms them into the spindle cells characteristic of KS. B cells, macrophages, vascular endothelial cells, and dendritic cells are also targets of infection. After initial infection, the virus maintains a latent stage in which LANA, vFLIP, and vCyclin are expressed. These latency proteins sustain KS cells through continued promotion of cell proliferation, anti-apoptotic effects, and immune evasion.

Angiogenesis and tumor microenvironment

KS is characterized by the formation of new blood and lymphatic vessels. HHV-8 vIL-6 and vMIP (viral macrophage inflammatory protein) induce expression of VEGF-A, VEGF-C, and VEGF-D, promoting blood/lymphatic vessel neoformation. KS lesions are complex lesions in which not only tumor cells but also reactive inflammatory cells (macrophages, T cells), endothelial cells, and spindle cells are mixed. The HIV Tat protein increases VEGFR (vascular endothelial growth factor receptor) expression in KS cells and directly promotes cell proliferation and invasion.

HIV-induced impairment of immune surveillance

Under normal immune conditions, HHV-8-specific CD8+ cytotoxic T lymphocytes (CTL) and NK cells eliminate HHV-8-infected cells. When CD4+ T-cell and CD8+ T-cell function is reduced by HIV, HHV-8-specific immune surveillance is impaired, raising the risk of HHV-8 reactivation and the development of KS. In addition, immune activation due to chronic HIV infection and the cytokine environment (elevated IL-6, IL-10, and TNF-α) create conditions favorable to HHV-8 replication and KS proliferation.


6. Symptoms

The clinical symptoms of AIDS-related Kaposi's sarcoma vary according to the site involved.

Skin lesions

This is the most common finding, appearing as purple, brownish-purple, or brown patches, papules, nodules, and plaques of the skin. It begins as bruise-like purple patch lesions and gradually progresses to raised nodules. It is widely distributed over the face (especially the nose, ears, and eyelids), oral mucosa (especially the hard palate), limbs, and trunk. KS lesions are usually painless, but pain occurs if nodules ulcerate or secondary infection is present.

Oral and mucosal lesions

Purple lesions appear on the oral mucosa, including the hard palate, gums, tongue, and tonsils. Oral KS can cause dysphagia, pain, and bleeding.

Lymphedema

When the lymphatic system is involved, non-pitting lymphedema of the lower limbs (mainly the dorsum of the foot and calf) occurs. Scrotal and perineal lymphedema are also possible. Lymphedema causes pain and impaired mobility.

Symptoms of visceral involvement

Pulmonary KS (about 20–30%): cough, dyspnea, fever. Gastrointestinal KS: abdominal pain, nausea and vomiting, bloody stool, bowel obstruction (rare but possible). Often asymptomatic, but severe bleeding can occur. Lymph node KS: lymphadenopathy. Liver/spleen KS: hepatomegaly and splenomegaly, upper abdominal discomfort.


7. Signs

On physical examination, multiple purple to brownish-purple skin lesions are typical. Purple lesions of the oral mucosa (especially the hard palate) and non-pitting edema of the lower limbs are characteristic findings of AIDS-related KS. Cervical, axillary, and inguinal lymphadenopathy may accompany.

Laboratory findings show a decreased CD4+ T-cell count and elevated HIV RNA. Detection of HHV-8 DNA in blood (quantitative PCR) is related to KS activity. Chest CT may show peribronchovascular nodules, patchy consolidation, bronchial wall thickening, pleural effusion (typically unilateral), and hilar lymphadenopathy. In pulmonary KS, the gallium scan tends to be negative (useful for differentiating from pulmonary infection). Abdominal CT may show lesions of the liver and spleen, intra-abdominal lymphadenopathy, and ascites.


8. Screening

Inspection of the skin and oral mucosa at regular outpatient visits of HIV-infected patients is important for early detection of AIDS-related KS. Systematic skin examination is recommended especially for HIV-infected MSM, HHV-8 seropositive patients, and patients with CD4 <200/μL. HHV-8 serologic testing (IgG ELISA) can be performed in HIV patients at high risk for KS (MSM, those of African origin); it should be recognized that in seropositive patients the risk of developing KS increases when CD4 declines. Some expert groups in the United States recommend regular HHV-8 screening in HIV-infected MSM, but there is not yet a universally adopted guideline.


9. Diagnosis

Definitive diagnosis of Kaposi's sarcoma is histopathologic. Biopsy of a skin lesion (punch or incisional biopsy) shows histologically spindle cells, vascular slits, extravasated red blood cells, and vacuolated cells. HHV-8 LANA-1 (ORF73) immunohistochemical staining that is strongly positive is the standard method that can confirm the diagnosis of KS. Clinical diagnosis of cutaneous KS from typical lesions has an accuracy of over 90%, but biopsy is required for final confirmation.

The AIDS Clinical Trials Group (ACTG) staging system is used for staging: T0 (skin-limited and/or lymph nodes) · T1 (visceral involvement or extensive oral KS), I0 (CD4 ≥150/μL) · I1 (CD4 <150/μL), S0 (none) · S1 (systemic symptoms). Chest CT and abdominal CT are performed to assess visceral involvement, bronchoscopy to confirm pulmonary involvement, and endoscopy to confirm gastrointestinal involvement.


10. Treatment

In the treatment of AIDS-related Kaposi's sarcoma, immune recovery through ART is the most important foundation.

ART

ART should be started immediately or optimized in all patients with AIDS-related KS. ART alone can produce complete remission in about 20–40% of skin-limited KS. When CD4 recovers, HHV-8-specific immunity is reconstituted and KS lesions regress. However, it should be recognized that after ART initiation, immune reconstitution inflammatory syndrome (KS-IRIS) may occur and lesions may worsen in the short term.

Topical treatment

For limited cutaneous KS, radiotherapy (RT), cryotherapy, intralesional vinblastine injection, and topical 9-cis retinoic acid (alitretinoin) are used as local treatment. Local treatment is given for cosmetic purposes or symptom relief.

Systemic chemotherapy

Systemic chemotherapy is applied for visceral involvement, extensive cutaneous KS (T1), severe lymphedema, and KS not responding to ART. Pegylated liposomal doxorubicin (PLD, Doxil/Caelyx) 20 mg/m² every 3 weeks is the current standard first-line systemic treatment, with a response rate of about 50–80%. Paclitaxel 100–135 mg/m² every 3 weeks is used as second-line treatment after PLD failure. The combination of vinblastine, bleomycin, and doxorubicin (ABV) is not currently preferred because of higher toxicity than PLD. Studies of antiangiogenic agents (bevacizumab) are ongoing.


11. Prognosis

The prognosis of AIDS-related Kaposi's sarcoma varies greatly according to stage, immune status, and response to ART. In ACTG T0/I0/S0 patients, median survival after ART is several years or more, and 5-year survival of 60–80% has been reported in those receiving ART and aggressive treatment. In high-risk groups with the combination of T1 (visceral involvement), I1 (CD4 <150/μL), and S1 (systemic symptoms), the prognosis is markedly poor. With pulmonary KS, median survival may be shortened to several months to 1 year. Median survival of AIDS-related KS before the ART era was about 14–18 months, but it has improved to an average of more than 5 years in the ART era. Even after KS reaches complete remission and CD4 recovers, HHV-8 remains latent, so there is a risk of recurrence upon immunosuppression.


12. Prevention

The most effective prevention of AIDS-related KS is maintaining high CD4 with ART. To block HHV-8 transmission, condom use and caution with oral sex are recommended. Because HHV-8 is also transmitted through saliva, reducing saliva contact is a theoretical preventive measure. There is still no approved vaccine against HHV-8, and development research is ongoing. In Africa, improving early access to ART is the key public health strategy for preventing KS. In HHV-8 seropositive HIV-infected individuals, starting and maintaining ART before CD4 declines is the most realistic approach to preventing KS.


13. References

  1. Bower M, Dalla Pria A, Coyle C, et al. Prospective stage-stratified approach to AIDS-related Kaposi's sarcoma. J Clin Oncol. 2014;32(5):409-414. DOI: 10.1200/JCO.2013.51.6757. PMID: 24378406.

  2. Schwartz RA. Kaposi's sarcoma: an update. J Surg Oncol. 2004;87(3):146-151. DOI: 10.1002/jso.20090. PMID: 15282701.

  3. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266(5192):1865-1869. DOI: 10.1126/science.7997879. PMID: 7997879.

  4. Martellotta F, Berretta M, Vaccher E, et al. AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies. Curr HIV Res. 2009;7(6):634-638. DOI: 10.2174/157016209789973619. PMID: 19929798.

  5. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. J Clin Oncol. 1997;15(9):3085-3092. DOI: 10.1200/JCO.1997.15.9.3085. PMID: 9294472.

  6. Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015;163(7):507-518. DOI: 10.7326/M14-2768. PMID: 26167721.

  7. Gbabe OF, Okwundu CI, Dedicoat M, Freeman EE. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults. Cochrane Database Syst Rev. 2014;(9):CD003261. DOI: 10.1002/14651858.CD003261.pub2. PMID: 25243866.

  8. Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10(10):707-719. DOI: 10.1038/nrc2888. PMID: 20865010.

  9. WHO. Guidelines on HIV-related cancer prevention, treatment and surveillance. WHO. 2022. ISBN: 9789240046085.

  10. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. DHHS. 2024. Section: Kaposi Sarcoma. https://clinicalinfo.hiv.gov/